

August 29, 2025

Alexion Notice Regarding Refunds to 340B Covered Entities

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, PLC (“Alexion”), has recalculated the 340B Ceiling Price for the product and corresponding national drug code (“NDC”) referenced below for the sales period of October 1, 2024 through December 31, 2024 (“Sales Period”). As a result of the recalculated 340B Ceiling Price, Alexion has determined a refund may be owed to 340B Covered Entities that purchased the below product during the Sales Period. Alexion is not seeking reimbursement or repayment where Covered Entities paid a lower price than the recalculated 340B ceiling price for the indicated time period, and any such amounts will not be used as offsets in determining the aggregate amount of any refund due.

The table below identifies the NDC, product, and Sales Period that are subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data submitted to the Centers for Medicare & Medicaid Services.

NDC 11	Product Description	340B Sales Period
25682-0028-01	Ultomiris 1100mg/11mL	4Q2024

Alexion will directly contact any Covered Entities that are entitled to an aggregated refund of \$10 or greater on how the refund will be processed. Alexion will not contact Covered Entities that are entitled to an aggregated refund across the Sales Period of less than \$10. Instead, Alexion is offering a refund to these 340B Covered Entities through this Notice.

If a 340B Covered Entity does not receive a communication from Alexion and that 340B Covered Entity believes it is entitled to a refund on the applicable NDC, then the 340B Covered Entity should contact Alexion at 340bnotice@alexion.com to request a refund. Please include “340B Refund-4Q2024” in the subject line and include the applicable 340B ID, Entity Name, NDC, Product Description, Quantity Purchased, Wholesaler and Invoice Date.

Alexion has asked the Health Resources and Services Administration (HRSA) to post this Notice on HRSA’s public website to ensure transparency to 340B Covered Entities. Please direct any questions and/or requests for additional information to Alexion at the following email address: 340bnotice@alexion.com.